CML Clinical Trials

Cancer research is an area where new treatments are being explored for the prevention, diagnosis and treatment of different types of cancer. Researchers conduct so called “clinical studies” or “clinical trials” to improve treatment options for the patients of today and tomorrow. These studies are performed to investigate the biological mechanisms of the disease, to optimize the use of existing therapies or to test new forms of treatment or new drugs to find out whether they are more effective or better tolerated. For more information please read our manual “what are clinical trials?”

Patients wishing to participate in clinical studies often look for a central source of information where they can find easy-to-understand facts on ongoing trials. CML Advocates Network is now hosting an inofficial database of current CML trials which have been initiated by academia (universities) or by pharmaceutical companies.

This database is run by patients for patients and is set up as a dynamic register in which data are updated on an ongoing basis.

CML Advocates Network has taken utmost care to verify the data entered, however, cannot assume any liability for the accuracy or completeness of the information. Patients should consult their doctor for personal advice and/or their scientific contact/study staff for the most up-to-date study information.

Do you know of any study that is not yet listed here? Please let us know by filling out this form. Or is there an entry which should be corrected? If so, please send us an email. Please also visit our forum if you have any questions or wish to share your experience on these studies.

9. Trials that are no longer recruiting

1 DACOTA = Decitabine with or without Hydroxyurea versus Hydroxyurea in CMML[Europe]

2 FAsciNation = Frontline Asciminib Combination in Chronic Phase CML (CML XI) [Germany]

3 INCB84344-102 = Safety and efficacy of ponatinib for recurrent or refractory leukemias or solid tumors in children [Europe]

4 Matchpoint – Ponatinib and Intensive Chemotherapy [UK]

5 OPTIC = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

7 CALLS = CML and ALL Low Level Mutation Study in the UK [UK]

6 DASFREE (CA180-406) = Discontinuation of dasatinib in CP-CML patients with stable MR4.5

8 RERISE China = Radotinib versus Imatinib [China]

9 ASC4MORE (CABL001E2201) = A Phase II Study of ABL001 in Patients With CML-CP without Deep Molecular Response [Asia, Australia, Europe, North America, South America]

10 TRAD = Treatment-free Remission Accomplished With Dasatinib in Patients With CML [Canada]

11 ENDURE = Efficacy and Safety of AOP2014 With CML Patients in Remission [France, Germany]

12 Prospective Registry of Ponatinib in Belgium [Belgium]

13 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]

14 DIALOG (CAMN107A2203) = Study of the Efficacy and Safety of Oral Nilotinib in CML in Children and Adolescents

15 Low Dose Dasatinib as First-Line Treatment [Middle East]

17 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]

18 ENESTPath Patient’s Voice Italian Substudy [Italy]

19 CA180-226 = Dasatinib Powder for Oral Suspension Substudy [Mexico, Romania, Spain, USA]

20 OPUS = Optimizing Ponatinib Use [Italy]

28 DASTOP-2 (CA180-655) = Second treatment stop [Denmark, Finland, France, Germany, Sweden, Norway, The Netherlands]

29 NAUT (CAMN107ADE22T) = Efficacy of nilotinib in inducing persistence of molecular remission after second or third TKI stop [Europe]

30 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]

31 BEST – Bosutinib in Elderly Chronic Myeloid Leukemia [Italy]

32 ENESTFreedom = Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

33 PIO2STOP = Second STOP After Pioglitazone Priming in CML Patients [France]

34 MSIT = Malaysia Stop Tyrosine Kinase Inhibitor Trial [Malaysia]

35 DECLINE (CAMN107ADE18T) = Imatinib versus nilotinib in CML in chronic phase [Germany]

36 CA180-357 = Decitabine + Dasatinib for Blast Phase CML

37 PF-114 Dose-finding Study in Ph+ CML Patients Resistant to 2nd Generation TKI or Presenting T315I Mutation [Russia]

38 ENESTop = A clinical research study evaluating the possibility to stop the drug nilotinib in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib treatment

39 OPTIC = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

40 Pioglitazone and TKI [USA]

41 TIGER (CML V) = Nilotinib or nilotinib + peginterferon with the aim to discontinue treatment

42 Ruxolitinib for CML with minimal residual disease [USA]

43 SIMPLICITY (CA180-330)

44 SPIRIT2 = Comparison of imatinib versus dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia Scientific title

45 BFORE (AV001) = Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

46 LAST Stopping Tyrosine kinase inhibitors

47 OPTIC 2L = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

48 CML-Paed II = Registration of Children with CML and Treatment with Imatinib [Germany]

49 EUROSKI (EUROStopKinaseInhibitor)

50 CHOICES = Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

51 EUREKA = ELN registry

52 ENESTPath = A Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML

53 Eltrombopag for thrombocytopenia in CML

54 DASCERN (CA180-399) = Phase IIb Study of Dasatinib versus Imatinib (Early Switch)

55 BYOND (B1871039) = Safety and Efficacy of Bosutinib in Ph+ CML Previously Treated with TKI

56 CA180-373 = A Phase 1B Study with Dasatinib plus Nivolumab in CML

57 LEONIDAS = Quality-of-Life effects of imatinib and dasatinib in CML